Detecting common mutations in MM patients through liquid biopsy
The detection of various gene mutations, such as those in Ras and Raf, are important for risk stratification and identifying appropriate treatment plans for multiple myeloma (MM) patients. This geneti... Author: VJHemOnc Added: 12/06/2017
I realize it’s been quite some TIME since I’ve written a post, almost a MONTH!, so today I decided to sit down and write one, and it’s going to be a long one, so get yourselves some tea and get comfy… CHAPTER ONE. PEEKABOO: in September I spent a lot of time researching possibly helpful but definitely non-toxic treatments for Peekaboo, my 11-year-old kitty whom I’ve written a lot about in recent times. She has a slipped disc, basically, and has been having a VERY hard time walking. The risk, of course, is that she’d stop walking altogether. Couldn’t let that happen! I...
ConclusionsPrompt and appropriate laboratory investigations ensure correct diagnosis of pseudohyperphosphatemia and help clinicians properly manage patients. To our knowledge, this patient is the first reported case of pseudohyperphosphatemia in patients with progression from SMM to MM.
Condition: Multiple Myeloma Intervention: Biological: IM21 CART Sponsors: Peking Union Medical College Hospital; Beijing Immunochina Medical Science&Technology Co., Ltd. Recruiting
Condition: Refractory Plasma Cell Myeloma Interventions: Drug: Dexamethasone; Biological: Elotuzumab; Drug: Pomalidomide Sponsors: Mayo Clinic; National Cancer Institute (NCI) Not yet recruiting
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.8b00880
British Journal of Haematology, EarlyView.
Condition: Multiple Myeloma Interventions: Drug: Daratumumab; Drug: velcade; Drug: Lenalidomide; Drug: dexamethasone Sponsors: European Myeloma Network; Janssen Research & Development, LLC Not yet recruiting
Conditions: Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma Interventions: Procedure: CS1-CAR T Therapy; Drug: Cyclophosphamide; Drug: Fludarabine; Procedure: Leukapheresis Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Not yet recruiting
Conditions: Cancer (Colon Cancer, Breast Cancer, Lymphoma, Multiple Myeloma); Elderly; Antineoplastic Agents; Cardiotoxicity Interventions: Other: Intensive cardiovascular monitoring; Other: No intervention Sponsors: Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León; IBSAL-Instituto de Investigación Biomédica de Salamanca, Fundación IECSCYL-IBSAL; Instituto de Salud Carlos III Not yet recruiting
Conditions: Multiple Myeloma; Relapsed and Refractory Multiple Myeloma Intervention: Drug: HG146 Sponsor: HitGen Ltd Active, not recruiting